The efficacy of Tenofovir-based therapy in patients showing suboptimal response to Entecavir-Adefovr combination therapy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Before tenofovir (TDF) become available in South Korea, combination therapy with entecavir (ETV) and adefovir (ADV) was the most potent regimen for chronic hepatitis B (CHB) patients who fail to respond to rescue therapy for drug resistance. We analyzed the efficacy of ETV-ADV combination therapy and investigated the clinical and clonal results of TDF-based rescue therapy in CHB patients refractory to this combination. Methods: We retrospectively reviewed the medical records of CHB patients treated for up to 3 years with ETV-ADV combination therapy as a rescue therapy for drug resistance. In cases refractory to this combination, clinical and clonal analyses were performed for TDF-based rescue therapy. Results: The analysis was performed on 48 patients. Twelve patients achieved a virological response (VR) within 3 years. A VR was subsequently achieved in nine of the ten patients without a VR who switched to TDF monotherapy. A VR was also achieved in six of the seven patients who switched to lamivudine-TDF combination therapy, and in two of the two patients who switched to ETV-TDF combination therapy. In an in vitro susceptibility test, viral replication was detected with TDF monotherapy but not with ETV-TDF combination therapy. Conclusions: The efficacy of ETV-ADV combination therapy was insufficient in CHB patients who were refractory to rescue therapy. A more potent regimen such as ETV-TDF combination therapy may be considered in such refractory cases.
Abstract
Background/Aims: Before tenofovir (TDF) become available in South Korea, combination therapy with entecavir (ETV) and adefovir (ADV) was the most potent regimen for chronic hepatitis B (CHB) patients who fail to respond to rescue therapy for drug resistance. We analyzed the efficacy of ETV-ADV combination therapy and investigated the clinical and clonal results of TDF-based rescue therapy in CHB patients refractory to this combination. Methods: We retrospectively reviewed the medical records of CHB patients treated for up to 3 years with ETV-ADV combination therapy as a rescue therapy for drug resistance. In cases refractory to this combination, clinical and clonal analyses were performed for TDF-based rescue therapy. Results: The analysis was performed on 48 patients. Twelve patients achieved a virological response (VR) within 3 years. A VR was subsequently achieved in nine of the ten patients without a VR who switched to TDF monotherapy. A VR was also achieved in six of the seven patients who switched to lamivudine-TDF combination therapy, and in two of the two patients who switched to ETV-TDF combination therapy. In an in vitro susceptibility test, viral replication was detected with TDF monotherapy but not with ETV-TDF combination therapy. Conclusions: The efficacy of ETV-ADV combination therapy was insufficient in CHB patients who were refractory to rescue therapy. A more potent regimen such as ETV-TDF combination therapy may be considered in such refractory cases.
참고문헌 (29)
- Ott JJ, "Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity", Vaccine, 30, pp.2212~2219 (2012)
- Lai CL, "Chronic hepatitis B--new goals, new treatment", N Engl J Med, 359, pp.2488~2491 (2008)
- Kim JH, "Molecular diagnosis and treatment of drug-resistant hepatitis B virus", World J Gastroenterol, 20, pp.5708~5720 (2014)
- Sang Soo Lee, "Type and cause of liver disease in Korea: single-center experience, 2005-2010", Clinical and Molecular Hepatology, 18(3), pp.309~315 (2012), 대한간학회[DOI]
- Zoulim F, "Management of treatment failure in chronic hepatitis B", J Hepatol, 56(Suppl 1), pp.S112~S122 (2012)
- Korean Association for the Study of the Liver, "KASL Clinical Practice Guidelines: Management of chronic hepatitis B", Clin Mol Hepatol, 18, pp.109~162 (2012)
- Liaw YF, "Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update", Hepatol Int, 6, pp.531~561 (2012)
- European Association For The Study Of The Liver, "EASL clinical practice guidelines: Management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
- Lok AS, "Chronic hepatitis B: update 2009", Hepatology, 50, pp.661~662 (2009)
- 김정한, "Hepatitis B surface antigen levels at 6 months after treatment can predict the efficacy of lamivudineadefovir combination therapy in patients with lamivudine- resistant chronic hepatitis B", Clinical and Molecular Hepatology, 20(3), pp.274~282 (2014), 대한간학회[DOI]
- Cho Y, "The efficacy of adefovir plus entecavir combination therapy in patients with chronic hepatitis B refractory to both lamivudine and adefovir", Dig Dis Sci, 58, pp.1363~1370 (2013)
- Jeon JW, "Efficacy of entecavir and adefovir combination therapy for patients with lamivudine- and entecavir-resistant chronic hepatitis B", Dig Dis Sci, 57, pp.1358~1365 (2012)
- Kim SS, "Adefovirbased combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B.", J Med Virol, 84, pp.18~25 (2012)
- Yang HJ, "Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir", lamivudine-resistant hepatitis B virus with or without adefovir resistance, 2012, pp.84, 424~430
- 박미성, "Antiviral efficacies of currently available rescue therapies for multidrug-resistant chronic hepatitis B", Clinical and Molecular Hepatology, 19(1), pp.29~35 (2013), 대한간학회[DOI]
- Lim YS, "Entecavir plus adefovir combination treatment for chronic hepatitis B patients after failure of nucleoside", nucleotide analogues, 2012, pp.17, 53~60
- Lim YS, "Randomized trial of entecavir plus adefovir in patients with lamivudine-resistant chronic hepatitis B who show suboptimal response to lamivudine plus adefovir", Antimicrob Agents Chemother, 56, pp.2941~2947 (2012)
- Yeon JE, "Resistance to adefovir dipivoxil in lamivudine resistant chronic hepatitis B patients treated with adefovir dipivoxil", Gut, 55, pp.1488~1495 (2006)
- Ahn SH, "The impact of the hepatitis B virus polymerase rtA181T mutation on replication and drug resistance is potentially affected by overlapping changes in surface gene", J Virol, 88, pp.6805~6818 (2014)
- Kwon SY, "Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients", J Virol, 84, pp.4494~4503 (2010)
- Melegari M, "Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective", Hepatology, 27, pp.628~633 (1998)
- 이초이, "Efficacy and Safety of Tenofovir-Based Rescue Therapy for Chronic Hepatitis B Patients with Previous Nucleo(s", t)ide Treatment Failure, 2014, pp.8(1), 64~69[DOI]
- 김효진, "Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients", The Korean Journal of Internal Medicine, 30(1), pp.32~41 (2015), 대한내과학회[DOI]
- Patterson SJ, "Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B", Gut, 60, pp.247~254 (2011)
- Petersen J, "Entecavir plus tenofovir combination as rescue therapy in pretreated chronic hepatitis B patients: an international multicenter cohort study", J Hepatol, 56, pp.520~526 (2012)
- Yip B, "Tenofovir monotherapy and tenofovir plus entecavir combination as rescue therapy for entecavir partial responders", Dig Dis Sci, 57, pp.3011~3016 (2012)
- 최강혁, "약제 내성 만성 B형간염 환자에서 테노포비어를 포함한 구원치료의 효과", 대한소화기학회지, 65(1), pp.35~42 (2015), 대한소화기학회
- Lee HW, "Viral evolutionary changes during tenofovir treatment in a chronic hepatitis B patient with sequential nucleos(t)ide therapy", J Clin Virol, 60, pp.313~316 (2014)
- 김지훈, "Is tenofovir disoproxil fumarate an all-powerful weapon in the treatment of chronic hepatitis B?", The Korean Journal of Internal Medicine, 30(1), pp.23~26 (2015), 대한내과학회[DOI]